<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4730">
  <stage>Registered</stage>
  <submitdate>3/11/2014</submitdate>
  <approvaldate>3/11/2014</approvaldate>
  <nctid>NCT02308254</nctid>
  <trial_identification>
    <studytitle>Drug Trial of Lixisenatide on Gastric Emptying and Blood Pressure Drops in Type 2 Diabetics and Healthy People</studytitle>
    <scientifictitle>Effects of Lixisenatide on Gastric Emptying, Glycaemia and 'Postprandial' Blood Pressure in Type 2 Diabetes and Healthy Subjects.</scientifictitle>
    <utrn />
    <trialacronym>Lixi</trialacronym>
    <secondaryid>130419</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Diabetes Mellitus</healthcondition>
    <healthcondition>Gastroparesis</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Lixisenatide
Treatment: drugs - Placebo

Active Comparator: Lixisenatide - Lixisenatide: 10 mcg, one subcutaneous injection dose

Placebo Comparator: Placebo - Matching placebo: one subcutaneous injection dose


Treatment: drugs: Lixisenatide
Abdominal administration

Treatment: drugs: Placebo
Abdominal administration

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Blood Pressure - Systolic and diastolic blood pressure (mmHg)</outcome>
      <timepoint>4.5 hours per study</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Heart rate - Heart rate (beats per minute)</outcome>
      <timepoint>4.5 hours per study</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Gastric emptying rate - Gastric retention (percent in the total stomach)</outcome>
      <timepoint>3 hours per study</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Blood glucose concentration - Blood glucose (mmol/L)</outcome>
      <timepoint>3 hours per study</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Healthy subjects:

               -  Male or female (females using appropriate contraceptive method or willing to
                  undergo pregnancy test)

               -  Body Mass Index (BMI) 19 - 30 kg/m2

          -  Type 2 Diabetic Patients:

               -  As per "healthy subjects"

               -  Type 2 diabetes (World Health Organisation (WHO) criteria) managed by diet alone
                  or on metformin

               -  Glycated haemoglobin &gt;6.0% and &lt;8.5%</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Subjects with a history of severe respiratory, cardiovascular, hepatic and/or renal
             disease (severe in that the social or physical manifestations of the disease, or
             living with the condition, impact negatively and significantly on the individuals'
             ability to lead a normal day to day life), chronic alcohol abuse or epilepsy (excluded
             by history) or if iron status, or liver function tests are outside the following
             ranges:

               1. Alanine aminotransferase (ALT) 0 - 55 U/L

               2. Alkaline phosphatase 30 - 110 U/L

               3. Aspartate transaminase 0 - 45 U/L

               4. Amylase and/or lipase &gt;3 x ULN

               5. Bilirubin 6 - 24 mmol/L

               6. Ferritin 15 - 200 ng/mL (females); 30 - 300 ng/mL (males)

               7. Haemoglobin 115 - 155 g/L (females); 135 - 172 g/L (males)

          -  Subjects with a creatinine clearance cut-off of &lt;50 ml/min

          -  Subjects requiring medication likely to influence blood pressure or gastrointestinal
             function

          -  Subjects with a past history of gastrointestinal disease, including known
             gastroparesis, significant upper gastrointestinal symptoms and previous gastric
             surgery

          -  Subjects with a past history of unexplained pancreatitis, chronic pancreatitis,
             pancreatectomy

          -  Subjects with a current or prior history of c-cell carcinoma

          -  Smoking &gt; 10 cigarettes/day

          -  Alchohol consumption &gt; 20 g/day

          -  Subjects who have donated blood in the previous 12 weeks

          -  Women of childbearing potential with no effective contraceptive method (defined as
             premenopausal, not surgically sterile women for at least 3 months prior to the time of
             screening) must have a confirmed negative urine B-hCG pregnancy test at screening
             visit. They must also use an effective contraceptive method throughout the study, and
             agree to repeat urine pregnancy test at designated visits.

          -  Lactation</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1/Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Unknown status</recruitmentstatus>
    <anticipatedlastvisitdate>1/04/2016</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital>Discipline of Medicine, Royal Adelaide Hospital - Adelaide</hospital>
    <postcode>5000 - Adelaide</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Royal Adelaide Hospital</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Sanofi</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>National Health and Medical Research Council, Australia</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine the effects of the drug lixisenatide on blood sugar
      levels, stomach emptying, blood pressure and heart rate, release of gut hormones and blood
      flow in the gut after a glucose drink in both healthy subjects and people with type 2
      diabetes. If lixisenatide is shown to be effective, it would encourage ongoing evaluation of
      its potential use in the management of the falls in blood pressure following a meal in
      diabetic patients.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02308254</trialwebsite>
    <publication>Schirra J, Houck P, Wank U, Arnold R, GÃ¶ke B, Katschinski M. Effects of glucagon-like peptide-1(7-36)amide on antro-pyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans. Gut. 2000 May;46(5):622-31.
Brennan IM, Feltrin KL, Horowitz M, Smout AJ, Meyer JH, Wishart J, Feinle-Bisset C. Evaluation of interactions between CCK and GLP-1 in their effects on appetite, energy intake, and antropyloroduodenal motility in healthy men. Am J Physiol Regul Integr Comp Physiol. 2005 Jun;288(6):R1477-85. Epub 2005 Feb 3.
Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, Schmiegel WH. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol. 1997 Nov;273(5 Pt 1):E981-8.
Little TJ, Pilichiewicz AN, Russo A, Phillips L, Jones KL, Nauck MA, Wishart J, Horowitz M, Feinle-Bisset C. Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses. J Clin Endocrinol Metab. 2006 May;91(5):1916-23. Epub 2006 Feb 21.
Delgado-Aros S, Kim DY, Burton DD, Thomforde GM, Stephens D, Brinkmann BH, Vella A, Camilleri M. Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. Am J Physiol Gastrointest Liver Physiol. 2002 Mar;282(3):G424-31.
Horowitz M, Nauck MA. To be or not to be--an incretin or enterogastrone? Gut. 2006 Feb;55(2):148-50.
Horowitz M, Rayner CK, Jones KL. Mechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes. Adv Ther. 2013 Feb;30(2):81-101. doi: 10.1007/s12325-013-0009-4. Epub 2013 Feb 13. Review.
Riddle M, Home P, Marre M, Niemoeller E, Ping L, Rosenstock J. Efficacy and safety of once-daily lixisenatide in type 2 diabetes insufficiently controlled with basal insulin Â± metformin: GetGoal-L Study. Diabetes 2012;61(Suppl 1):A212-A344 (Abstract 983-P).
Rosenstock J, Forst T, Aronson R, et al. Efficacy and safety of once-daily lixisenatide added on to titrated glargine plus oral agents in type 2 diabetes: GetGoal-Duo 1 Study. Presented at the 72nd Scientific Sessions of the American Diabetes Association, Philadelphia PA, 8-12 June 2012 (Abstract 62-OR).
AhrÃ©n B, Dimas L, Miossec P, Saubado S, Aronson R. Efficacy and safety of lixisenatide QD morning and evening injections vs placebo in T2DM inadequately controlled on metformin (GetGoal-M). Oral presentation at the 21st World Diabetes Congress, Dubai, UAE, 8 December 2011 (Abstract 0-0591).
Ratner R, Hanefield M, Shamanna P, et al. Efficacy and safety of lixisenatide once daily versus placebo in patients with T2DM insufficiently controlled on sulfonylurea + metformin (GetGoal-S). Poster presented at 47th Annual Meeting of the European Association for the Study of Diabetes, 12-16 September 2011, Lisbon, Portugal. Diabetologia 2011;54(Suppl 1):1-542 (Abstract 785).
Pinget M, Goldenberg R, Niemoeller E, Muehlen-Bartmer I, Aronson R. Efficacy and safety of lixisenatide once daily versus placebo in patients with type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P). Diabetes 2012;61(Suppl 1):A212-A344 (Abstract 1010-P).
Rosenstock J, Raccah D, Koranyi L, et al. Efficacy and safety of lixisenatide once daily versus exenatide twice daily in patients with T2DM insufficiently controlled on metformin (GetGoal-X). Poster presented at 47th Annual Meeting of the European Association for the Study of Diabetes, 12-16 September 2011, Lisbon, Portugal. Diabetologia 2011;54(Suppl 1):1-542 (Abstract 786).
Bolli G, Munteanu M, Dotsenko S, Niemoeller E, Boka G, Hanefield M. Efficacy and safety of lixisenatide once-daily versus placebo in patients with T2DM insufficiently controlled on metformin (GetGoal-F1). Poster presented at 47th Annual Meeting of the European Association for the Study of Diabetes, 12-16 September 2011, Lisbon, Portugal. Diabetologia 2011;54(Suppl 1): 1-542 (Abstract 784).
Fonseca VA, Alvarado-Ruiz R, Raccah D, Boka G, Miossec P, Gerich JE; EFC6018 GetGoal-Mono Study Investigators. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). Diabetes Care. 2012 Jun;35(6):1225-31. doi: 10.2337/dc11-1935. Epub 2012 Mar 19.
Meier JJ, Kemmeries G, Holst JJ, Nauck MA. Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects. Diabetes. 2005 Jul;54(7):2212-8.
Christensen M, Knop FK, VilsbÃ¸ll T, Holst JJ. Lixisenatide for type 2 diabetes mellitus. Expert Opin Investig Drugs. 2011 Apr;20(4):549-57. doi: 10.1517/13543784.2011.562191. Epub 2011 Mar 11. Review.
Jansen RW, Lipsitz LA. Postprandial hypotension: epidemiology, pathophysiology, and clinical management. Ann Intern Med. 1995 Feb 15;122(4):286-95. Review.
Shannon JR, Diedrich A, Biaggioni I, Tank J, Robertson RM, Robertson D, Jordan J. Water drinking as a treatment for orthostatic syndromes. Am J Med. 2002 Apr 1;112(5):355-60.
Vanis L, Gentilcore D, Lange K, Gilja OH, Rigda RS, Trahair LG, Feinle-Bisset C, Rayner CK, Horowitz M, Jones KL. Effects of variations in intragastric volume on blood pressure and splanchnic blood flow during intraduodenal glucose infusion in healthy older subjects. Am J Physiol Regul Integr Comp Physiol. 2012 Feb 15;302(4):R391-9. doi: 10.1152/ajpregu.00464.2011. Epub 2011 Nov 30.
Jones KL, Tonkin A, Horowitz M, Wishart JM, Carney BI, Guha S, Green L. Rate of gastric emptying is a determinant of postprandial hypotension in non-insulin-dependent diabetes mellitus. Clin Sci (Lond). 1998 Jan;94(1):65-70.
O'Donovan D, Feinle C, Tonkin A, Horowitz M, Jones KL. Postprandial hypotension in response to duodenal glucose delivery in healthy older subjects. J Physiol. 2002 Apr 15;540(Pt 2):673-9.
Mathias CJ. Postprandial hypotension. Pathophysiological mechanisms and clinical implications in different disorders. Hypertension. 1991 Nov;18(5):694-704. Review.
Edwards CM, Todd JF, Ghatei MA, Bloom SR. Subcutaneous glucagon-like peptide-1 (7-36) amide is insulinotropic and can cause hypoglycaemia in fasted healthy subjects. Clin Sci (Lond). 1998 Dec;95(6):719-24.
BarragÃ¡n JM, RodrÃ­guez RE, Eng J, BlÃ¡zquez E. Interactions of exendin-(9-39) with the effects of glucagon-like peptide-1-(7-36) amide and of exendin-4 on arterial blood pressure and heart rate in rats. Regul Pept. 1996 Nov 14;67(1):63-8.
White J. Efficacy and safety of incretin based therapies: clinical trial data. J Am Pharm Assoc (2003). 2009 Sep-Oct;49 Suppl 1:S30-40. doi: 10.1331/JAPhA.2009.09079. Review.
Gentilcore D, Bryant B, Wishart JM, Morris HA, Horowitz M, Jones KL. Acarbose attenuates the hypotensive response to sucrose and slows gastric emptying in the elderly. Am J Med. 2005 Nov;118(11):1289.
Stevens JE, Horowitz M, Deacon CF, Nauck M, Rayner CK, Jones KL. The effects of sitagliptin on gastric emptying in healthy humans - a randomised, controlled study. Aliment Pharmacol Ther. 2012 Aug;36(4):379-90. doi: 10.1111/j.1365-2036.2012.05198.x. Epub 2012 Jun 28.
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.
Jones KL, MacIntosh C, Su YC, Wells F, Chapman IM, Tonkin A, Horowitz M. Guar gum reduces postprandial hypotension in older people. J Am Geriatr Soc. 2001 Feb;49(2):162-7.
Gentilcore D, Nair NS, Vanis L, Rayner CK, Meyer JH, Hausken T, Horowitz M, Jones KL. Comparative effects of oral and intraduodenal glucose on blood pressure, heart rate, and splanchnic blood flow in healthy older subjects. Am J Physiol Regul Integr Comp Physiol. 2009 Sep;297(3):R716-22. doi: 10.1152/ajpregu.00215.2009. Epub 2009 Jun 24.
Gentilcore D, Hausken T, Meyer JH, Chapman IM, Horowitz M, Jones KL. Effects of intraduodenal glucose, fat, and protein on blood pressure, heart rate, and splanchnic blood flow in healthy older subjects. Am J Clin Nutr. 2008 Jan;87(1):156-61.
Langewouters GJ, Settels JJ, Roelandt R, Wesseling KH. Why use Finapres or Portapres rather than intra-arterial or intermittent non-invasive techniques of blood pressure measurement? J Med Eng Technol. 1998 Jan-Feb;22(1):37-43.
Moneta GL, Taylor DC, Helton WS, Mulholland MW, Strandness DE Jr. Duplex ultrasound measurement of postprandial intestinal blood flow: effect of meal composition. Gastroenterology. 1988 Nov;95(5):1294-301.
Iwao T, Toyonaga A, Shigemori H, Oho K, Sumino M, Sato M, Tanikawa K. Echo-Doppler measurements of portal vein and superior mesenteric artery blood flow in humans: inter- and intra-observer short-term reproducibility. J Gastroenterol Hepatol. 1996 Jan;11(1):40-6.
Zwolak RM, Fillinger MF, Walsh DB, LaBombard FE, Musson A, Darling CE, Cronenwett JL. Mesenteric and celiac duplex scanning: a validation study. J Vasc Surg. 1998 Jun;27(6):1078-87; discussion 1088.
Shimamoto H, Kito H, Kawazoe K, Fujita T, Shimamoto Y. [Validation of Doppler arterial flow in humans]. Kokyu To Junkan. 1992 Jul;40(7):673-6. Japanese.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Karen L Jones, PhD</name>
      <address>University of Adelaide, Royal Adelaide Hospital</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Rachael S Tippett, BSc Honours</name>
      <address />
      <phone>8222 2915</phone>
      <fax />
      <email>rachael.tippett@adelaide.edu.au</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>